Covaxin shows 81% efficacy

Subject: Science and Technology

Context: Bharat Biotech reportedinterim clinical efficacy of 81% in the phase 3 clinical trial of its vaccine Covaxin.

Concept:

Covaxin is India’s first indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR).
It is an inactivated vaccine (do not replicate and are therefore unlikely to revert and cause pathological effects). They contain dead virus, incapable of infecting people but still able to instruct the immune system to mount a defensive reaction against an infection.
COVAXIN is included along with immune-potentiators, also known as vaccine adjuvants, which are added to the vaccine to increase and boost its immunogenicity.
It is a 2-dose vaccination regimen given 28 days apart.
It is a vaccine with no sub-zero storage, no reconstitution requirement, and ready to use liquid presentation in multi-dose vials, stable at 2-8 degree C.
Earlier the vaccine received DCGI approval for Phase I & II Human Clinical Trials in July, 2020.
COVAXIN was granted approval for emergency restricted use in India by DCGI-CDSCO on Jan 03, 2021 with efficacy data for Phase-3 data pending.

More about efficacy data

covaxin demonstration